For each patient, the proportion was calculated as the percent of all days spent in hospital postrandomization, which was a highly skewed distribution. Days on which a patient was unable to comply with a treatment and did not receive it were not counted as treatment days. . For each week total patient numbers in each group represent those patients still in hospital. For each specialism type a patient was defined as receiving that therapy type if it was delivered at least once, based on a pre-defined taxonomy to describe therapy types during the trial. The therapies were delivered by specialist staff for the usual care group or specialist staff and/or the dedicated rehabilitation assistant for the intervention group. The proportions do not reflect treatment intensity or sub-type; these are described in table 2 (main manuscript) and table 1e (above). An individualised goal was defined as an agreed, documented patient-centred rehabilitation goal (for example a specific activity). OT, occupational therapy; PT, physiotherapy; SLT, speech and language therapy. Total cost is defined as all secondary care admissions/attendance from the date of randomization to 1 year follow-up. Monetary values were assigned to the primary care/questionnaire data collected during the trial, but this was not included in the final analysis due to the magnitude and pattern of this missing data. The baseline cost is defined as secondary care patient resource-use prior to randomization (primarily ICU-related costs) and was included as a separate variable. This variable was not included in the reported analysis but was included as a covariate in the sensitivity analysis. The inclusion of the baseline cost variable in the regression model did not change the overall conclusion but it did slightly raise the costs for the GRA arm of the trial. The costing methodology for the secondary care resource-use was based on a per-diem approach using Scottish Health Service costs in line with the trial protocol paper.
eAppendix. Summary of Health Economic Evaluation
An economic component was integrated into the study to evaluate the cost-effectiveness of the intervention from the perspective of the UK NHS on the basis of intention-to-treat.
The mean cumulative cost for the intervention group was £48,953 compared to £49,057 for the control group (see table e5 ). An analysis of the distribution of cost illustrated that this potential cost differential in favour of the intervention was illusory, and was driven solely by the skewed distribution of cost and the long right hand tail of the control group.
Robust and generalised linear regression models were used to account for the skewed cost distribution and estimate any additional costs associated with delivering the intervention. The point estimate from the regression model considered the intervention to lead to an additional £2,107 although this was not significantly different from zero (95% CI: -£3883 to £8096). Table e6 presents the regression results for the analysis of cost and health-related quality of life (HRQoL) as measured by SF-12v2. Exploratory analyses were undertaken to assess whether cumulative costs and quality-adjusted life years (QALYs) should be simultaneously estimated given the potential dependence between the two variables. The results from the Breusch-Pagan Test of Independence suggested that it was not possible to reject the assumption of independence. This result held for both completecase and imputed SF-6D data. Cost and QALYs were, therefore, estimated independently and combined to report results on the cost-effectiveness for all model specifications and sensitivity analyses. Figure 2e presents the incremental cost-effectiveness plane based on the multiple imputation of missing quality of life data.
Mean imputation was used for two observations (one from each treatment group) which did not have any hospital cost estimates due to missing discharge data. The pattern of missingness for SF-6D, which was used in the construction of QALYs, was explored to assess if the variables exhibited a monotone pattern of missingness.
Multivariate imputation by chained equations was used to address missing data on SF-6D at 3, 6 and 12 months.
Sensitivity analysis of imputation methods were undertaken by adopting alternative imputation methods, such as univariate regression based models and predictive mean matching. The results were qualitatively similar across all imputation approaches. However, the results for the quality of life gains for the complete-case analysis were sensitive to the imputation of SF-6D utility values for patient deaths. If deaths are excluded from the analysis, the intervention was estimated to lead to an additional five days in good health over the one year trial period.
The results from the complete-case analysis considered the intervention to be more expensive and less effective once patient deaths were included in the HRQoL equation. Furthermore, the results based on the imputed SF- 6D data also estimated the intervention to be more expensive and less effective, as illustrated with the point estimate of the incremental cost-effectiveness ratio (ICER) lying in the North West quadrant in Figure 2e . The interpretations of the health economic results remain persistent and persuasive that the intervention should not be considered for implementation in the UK NHS based on this analysis. This rationale is reflected in the ICER for the complete case analysis being dominated by usual care and the intervention being well in excess of conventional willingness to pay levels.
The study prioritised data collection and follow-up of the primary clinical outcome. One consequence of this approach was that there were concerns regarding the quality of primary care resource-use data, which relied on completion of questionnaires by participants. There was a significant proportion of missing data across primary care use of patient services, which limited the applicability of multiple imputation methods. The results for the cumulative costs were, therefore, confined to secondary care. This approach does not limit the generalisability of the results as the magnitude of the cost differential for primary care resource use will be dominated by the secondary care needs for the study population.
